Two co-founders of Fullerton Healthcare Corporation have faced financial penalties totalling S$160,000 for their involvement in a scheme to falsify entertainment expense claims spanning more than S$211,000. Daniel Chan Pai Sheng and Michael Tan Kim Song, both 52-year-old physicians, were convicted in Singapore's District Court following guilty pleas in July, marking a significant conclusion to an investigation into financial irregularities within the healthcare investment group.
The case reveals a troubling pattern of fabricated KTV and entertainment receipts that masked the true nature of financial transfers within the company. Rather than enriching themselves, court documents indicate the inflated claims were engineered to channel funds to Collin Chiew, a 58-year-old insurance executive with a separate pending case. Chiew had previously served as chief executive of Aon Singapore from January 2015 to July 2018, establishing his credentials in Singapore's professional services sector before his involvement in this matter. The court filings did not clarify whether Chiew ultimately received the disputed amount, leaving a critical gap in understanding the full scope of the scheme.
Chan received the heavier sentence of the two, facing a S$135,000 fine after pleading guilty to five counts of falsifying company accounts. The inflated claims he processed exceeded S$336,000 in total, with actual expenditures amounting to only approximately S$125,000—a discrepancy of more than S$211,000. This substantial gap illustrates the systematic nature of the fraudulent documentation. Tan, by comparison, was fined S$25,000 after admitting to a single count of falsification involving approximately S$82,000 in false claims against actual expenses of roughly S$42,000, resulting in a padding of nearly S$40,000. These individual cases formed portions of the larger conspiracy involving the co-founders.
Initially, both men faced multiple charges related to corruption and graft. However, prosecutors exercised discretionary authority to discharge all graft-related offences without entering acquittals, a legal mechanism permitting future prosecution should material new evidence surface. This prosecutorial approach suggests either evidentiary limitations or strategic considerations regarding the primary focus on falsification charges. The decision underscores the complexity of white-collar investigations in healthcare and professional services sectors across Southeast Asia, where distinguishing between intent and administrative irregularity can prove legally challenging.
The broader Fullerton Healthcare situation extended beyond the two convicted co-founders. David Sin, a third principal of the organisation, separately pleaded guilty in August 2025 to six counts of falsification of accounts and received an identical S$160,000 fine. Sin's parallel case indicates systematic problems within the entity's financial controls and corporate governance structures. The repetition of charges and similar penalties across multiple individuals suggests institutional vulnerability rather than isolated misconduct, raising questions about oversight mechanisms within the company during the relevant period.
Chan held directorship roles within Fullerton Healthcare Group (FHG), a healthcare services subsidiary, while simultaneously serving as president of Fullerton Health China. Tan maintained his directorial position within FHG. Both men have since relinquished these posts, signalling attempts to distance the reorganised company from the individuals involved in the falsification scheme. The corporate structure itself—with FHC functioning as an investment holding entity overseeing multiple operational subsidiaries—created the layered environment within which the scheme operated relatively undetected for years.
The timeline of events originated in 2010 when Tan and Chan co-founded FHG to deliver healthcare services through networks of medical professionals and facilitate insurance claim processing for clients. This service-oriented model positioned the company within Southeast Asia's expanding healthcare and insurance sectors. Around 2012, their introduction to Chiew marked a turning point. By 2015, when Chiew requested financial assistance citing personal circumstances including child education and property expenses, the groundwork for the falsification scheme was essentially laid. Rather than pursuing transparent lending arrangements or salary supplements, the co-founders opted for the elaborate system of fabricated entertainment receipts.
Chan's frequent business trips to Hong Kong—approximately twice monthly from 2015 onwards—provided the operational framework for executing the scheme. Before each journey, he would arrange with Sin for inflated or entirely false KTV receipts, which Tei Chu Pink, a 46-year-old associate, would physically prepare. The mechanics were straightforward: Chan would occasionally make nominal payments at establishments using personal funds, other times make no payment whatsoever, then collect falsified documentation showing substantial entertainment expenses. Upon returning to Singapore, these receipts were channelled through unspecified FHC personnel or Fullerton Health China employees for processing into company expense systems.
The deputy public prosecutors' court submissions detailed deliberate decision-making rather than accident or administrative oversight. Both Tan and Chan possessed full knowledge of the scheme's operation, with prosecutors establishing specific instances of conspiracy, including a 2016 incident where all three principals—Tan, Chan, and Sin—coordinated to falsify a single entertainment claim. This level of coordination across multiple years and numerous transactions demonstrates premeditation and sophistication in evading detection. The involvement of Tei, positioned as the document fabricator, suggests a supporting ecosystem of enablers willing to participate in the illegal scheme.
For Malaysian and broader Southeast Asian readers, this case illustrates vulnerabilities within regional business ecosystems, particularly in sectors combining healthcare operations with financial services and international subsidiaries. The ability of three experienced professionals to operate a multi-year falsification scheme without immediate detection reflects gaps in internal controls, audit procedures, and governance oversight that may extend beyond Fullerton Healthcare. Healthcare investment groups frequently operate across multiple jurisdictions, requiring robust compliance frameworks. The case also demonstrates that even educated professionals with substantial professional standing may succumb to organisational pressure or misguided loyalty, compromising integrity in the process.
The Singapore authorities' investigation and prosecution signal strengthened enforcement of financial accountability standards. The Corrupt Practices Investigation Bureau's involvement elevated the matter beyond routine accounting irregularities to potential corruption considerations, though ultimate convictions focused narrowly on falsification. This distinction carries implications for how regional regulators approach similar cases involving financial services, healthcare, and professional services sectors. Companies throughout Southeast Asia should examine their expense verification procedures, particularly for entertainment and overseas travel claims that create natural opportunities for inflation or fabrication.
The broader business implications extend to corporate governance and the relationship between principals and employees across regional ventures. The scheme's reliance on multiple individuals executing specific roles—receipt fabricators, finance processing staff, executive approvers—highlights how organisations can inadvertently create conditions enabling fraud when oversight structures remain insufficiently robust. For stakeholders in Malaysian healthcare and financial services sectors, the case underscores the importance of independent audit functions, segregation of duties, and clear policies governing approval authority for claims and expenses. The penalties imposed, while substantial in absolute terms, constitute a relatively modest cost relative to the amounts falsified, potentially failing to deter similarly inclined actors in wealthier operations.
